An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.» Read More
European shares are expected to open flat Friday, though concerns about the euro zone debt crisis linger and could weigh on markets.
The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.
A handful of biopharma stocks could be pretty volatile this week and we're talking right up until Friday.
Deal making is officially back on with three major takeovers announced Monday. Where is the Fast Money finding alpha amid increasing acquisitions?
Results of a new study could change the way elderly patients with vision trouble are treated and have financial implications for Swiss drug giants Novartis and Roche.
Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.
It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer.
M&A expert Howard Lanser reveals the next sector where he expects to see a big uptick in takeovers!
Even in this anemic market, it appears the urge to merge is alive and well.
The Dow fell modestly in choppy trade after comments from billionaire investor Warren Buffett dragged down sentiment on Monday.
Could Merck’s acquisition of Schering-Plough trigger a slew of M&A deals?
A rally in the last hour of trading lifted the Dow into positive territory on Friday, as surging oil prices drove energy stocks...
About to make a move? First, find out where Karen Finerman says there’s too much risk and too little reward to get involved.
In this Web Extra the traders game the Genentech takeover. Will Roche pull it off?
The Dow closed lower on Wednesday after President Obama warned of stricter oversight for Wall Street, raising the specter of greater regulation that investors fear could sap profits.
With the market at a 12-year low, it's a healthy exercise to try and find some good things in this world. Here are 5 things we bet you didn't think of...
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
If you’re looking for trading action look no farther than healthcare. There’s something happening in almost every corner of this sector.
The guys go behind the headlines and give you their take on the dismal economics numbers that capped off the worst January ever. But there are still places where you can make fast money.
With word today that Roche is going hostile and cutting the price of its bid for shares of Genentech, what should be the first questions on the minds of investors?